A Randomized, Multi Center, Phase IIIb Open-label Study to Evaluate the Efficacy of Sequential Therapy of Peginterferon Alfa-2a(Pegasys(TM)) Following Entercavir Compared With Peginterferon Alfa-2a Monotherapy in Patient With HBeAg Positive Chronic Hepatitis B.
Phase of Trial: Phase III
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Entecavir
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms POTENT
- 10 Nov 2012 Interim results presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases.
- 10 Nov 2012 Primary endpoint 'Seroconversion-rate' has not been met.
- 25 Aug 2011 New source identified and integrated (Korean Clinical Trials Register KCT0000042).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History